Mexico The latest news from Mexican pharma, including Bayer’s big bet on oncology and Novartis’ aggressive expansion strategy as well as updates on the country’s vaccination drive, including the upcoming rollout of the J&J jab, why the country’s doctors are being denied vaccines, and the progression of trials for the Sanofi…
Asia-Pacific The latest from the pharma industry in Southeast Asia, including underwhelming results from Kalbe Pharma, Indonesia’s largest pharma company; Novavax’s vaccine manufacturing plans in the Philippines; the promising future of cannabis in Thailand; and the first Vietnamese coronavirus vaccine candidate’s Phase III trials. Indonesia’s Kalbe Farma sales underwhelm investors…
France The latest news from French pharma, including why President Emmanuel Macron’s initiative to bring medical production back to Europe has hit a wall, Sanofi’s slow progress towards finally bringing its COVID-19 vaccine candidate to market, and why investors are still betting on Valneva. Macron’s Push for German Pharma Alliance…
China The latest news from Chinese pharma, including an overhaul of the country’s patent law; a BioNTech-Fosun tie-up on COVID-19 vaccines; and big R&D subsidies for local companies available in Shanghai. How Hong Kong can cement its position as a biotech listing hub (SCMP) https://www.scmp.com/comment/opinion/article/3134767/how-hong-kong-can-cement-its-position-biotech-listing-hub To maintain its growth and…
Germany The latest news from German pharma, including a new US leadership team and more COVID-related investment at Merck KGaA; the CureVac vaccine’s role in fighting COVID-19 variants; and why the country is trailing its European neighbours in digital health. Merck KGaA’s new CEO shakes up U.S. leadership to spark…
India The latest from Indian pharma, including the year-to-year 51.5 percent growth of the pharma market in April, Lilly’s partnership with three generics makers to expand the availability of its arthritis drug baricitinib, Zydus Cadila’s upcoming approval of its COVID-19 vaccine, and the emergency use authorization for a COVID-19 antibody drug…
Japan The latest from Japanese pharma, including Takeda’s big profit jump, British Linepharma’s quest to get the first ever induced abortion pill for practical use, Shionogi’s promise to become the first Japanese company to get a COVID-19 vaccine approved, and the Japanese industry’s opposition to the Biden administration’s support for a…
Spain The latest from Spanish pharma, including the acquisition of PTS by a private equity group for its nanoparticle drug delivery technologies; the agreement between Esteve and Kowa to license an acute pain product currently in Phase III; and the growth of the Spanish pharma market in February after falling 4…
Korea The latest news from Korean pharma, including how Korea can put the infrastructure in place to develop a homegrown blockbuster drug; Prestige Biopharma’s move to open a vaccine facility; and Samsung Bioepis’ first steps into the Australian market. ‘Now is best time to develop Korean blockbuster drug’ (Korea Biomedical…
MEA The latest Middle East and North Africa (MENA) pharma, including Egypt’s opening of the largest “pharmaceutical city” in the Middle East and Abu Dhabi’s quest to become a pharma hub with the goal of distributing billions of vaccines. Turkish Koçak Farma’s COVID-19 vaccine has begun Phase I clinical trials…
China The latest China pharma news, including the upcoming first domestic approval for a foreign COVID-19 vaccine in June; the potential of Western China as a manufacturing hub; and EpimAb’s plan for a public stock offering in 2022 amid a booming global bispecific antibodies market. Pharma Not Immune From Coming…
UK The latest UK pharma news, including how new investment in GSK stands to reshape the country’s iconic pharma giant; CDMO Sterling’s latest acquisition; and calls for a national registry to capture company payments to clinicians and patient support groups. The 30 fastest-growing unquoted pharma companies in the UK (Consultancy.uk)…
See our Cookie Privacy Policy Here